Olanzapine for Treating Anorexia Nervosa in Teen Girls
Author Information
Author(s): Wendy Spettigue, Annick Buchholz, Katherine Henderson, Stephen Feder, David Moher, Kader Kourad, Isabelle Gaboury, Mark Norris, Sheila Ledoux
Primary Institution: Children's Hospital of Eastern Ontario Research Institute
Hypothesis
Adolescents diagnosed with a severe eating disorder and treated with olanzapine will demonstrate reduced disordered eating attitudes and behaviors as well as an increased rate of weight gain compared to a control group treated with placebo.
Conclusion
The study aims to evaluate the effectiveness and safety of olanzapine in improving eating attitudes and behaviors in adolescent females with anorexia nervosa.
Supporting Evidence
- Anorexia Nervosa is a serious condition that often develops in adolescence and is predominantly found in females.
- Current treatments for anorexia include medical, nutritional, and psychological interventions, but pharmacotherapy evidence in youth is limited.
- Olanzapine is hypothesized to help with weight gain and reduce anxiety in adolescents with anorexia.
Takeaway
This study is looking at whether a medicine called olanzapine can help girls with a serious eating problem feel better and gain weight.
Methodology
This is a randomized, double-blind, placebo-controlled trial involving adolescent females aged 12 to 17 diagnosed with anorexia nervosa.
Potential Biases
Potential biases may arise from the reliance on self-reported measures and the subjective nature of psychological assessments.
Limitations
The study may have limitations related to the small sample size and the generalizability of the findings to broader populations.
Participant Demographics
Adolescent females aged 12 to 17 with anorexia nervosa or Eating Disorder Not Otherwise Specified.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website